Regulatory Expertise MMSTAN comprises former U.S. FDA Drug Investigators and industry regulatory experts, offering credibility in navigating regulatory expectations. Potential up-sell: expand into end-to-end compliance programs, pre-inspection readiness, and audit preparation services for drugs, biologics, and medical devices.

NAI/VAI Track A proven track record of achieving No Action Indicated or Voluntary Action Indicated statuses signals strong value in inspection outcomes. Sales opportunity: package premium inspection support, gap remediation plans, and ongoing regulatory surveillance to help clients maintain favorable inspection results.

Lifecycle Compliance Services span the pharmaceutical product lifecycle with a cost-effective model. Upsell potential to mid-market and enterprise pharma/biotech firms seeking scalable compliance solutions, training programs, and documentation management across development, manufacturing, and post-market surveillance.

Tech Stack Fit Utilizes common enterprise tools (WordPress, Microsoft 365, Windows Server, ASP.NET, PHP) suggesting potential for client-facing digital solutions and secure collaboration. Opportunity to offer regulatory repository platforms, audit trails, and compliance dashboards hosted or integrated with clients’ existing IT ecosystems.

Growth Readiness Revenue is in the sub-$1M range with a lean team, indicating nimbleness and potential for rapid expansion through strategic partnerships. Target growth channels: channel partnerships with larger regulatory services firms, white-label consulting offerings, and entry into adjacent markets like medical devices and biologics with scalable service bundles.